Martina Venturini

Florence, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Protective effects of adenosine A2B receptor antagonism in a cuprizone-induced demyelination model.

Protective effects of adenosine A2B receptor antagonism in a cuprizone-induced demyelination model.

Journal: Neuropharmacology
Published: January 08, 2026

Human Foetal Neuroblasts Exhibit BK Channel-Dependent Membrane Voltage Oscillations upon Depolarization.

Human Foetal Neuroblasts Exhibit BK Channel-Dependent Membrane Voltage Oscillations upon Depolarization.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: December 31, 2025

Cutamesine attenuates hippocampal damage via sigma-1 receptor activation following oxygen-glucose deprivation in vitro.

Cutamesine attenuates hippocampal damage via sigma-1 receptor activation following oxygen-glucose deprivation in vitro.

Journal: Brain research
Published: October 08, 2025

Multicenter Translational Trial of Remote Ischemic Conditioning in Acute Ischemic Stroke (TRICS BASIC).

Multicenter Translational Trial of Remote Ischemic Conditioning in Acute Ischemic Stroke (TRICS BASIC).

Journal: Stroke
Published: September 26, 2025

Adenosine A2A receptor blockade promotes oligodendrocyte differentiation and myelination: Highlighting the potency of an edaravone-conjugated A2A receptor antagonist.

Adenosine A2A receptor blockade promotes oligodendrocyte differentiation and myelination: Highlighting the potency of an edaravone-conjugated A2A receptor antagonist.

Journal: Neuropharmacology
Published: July 08, 2025

8-Amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives hybridized with antioxidants: new highly potent and selective human A2A adenosine receptor antagonists as useful agents against cerebral ischemia.

8-Amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives hybridized with antioxidants: new highly potent and selective human A2A adenosine receptor antagonists as useful agents against cerebral ischemia.

Journal: Bioorganic chemistry
Published: June 18, 2025

Protection From Demyelination by the Novel Adenosine Dual A2A/A2B Receptor Antagonist P626 in EAE and Cultured Oligodendrocyte Precursor Cells.

Protection From Demyelination by the Novel Adenosine Dual A2A/A2B Receptor Antagonist P626 in EAE and Cultured Oligodendrocyte Precursor Cells.

Journal: Journal of cellular and molecular medicine
Published: April 13, 2025

Anti-nociceptive action of leonurine through TRPA1 and TRPV4 channels modulation.

Anti-nociceptive action of leonurine through TRPA1 and TRPV4 channels modulation.

Journal: British journal of pharmacology
Published: February 03, 2025

Dual action of sphingosine 1-phosphate pathway in in vitro models of global cerebral ischemia.

Dual action of sphingosine 1-phosphate pathway in in vitro models of global cerebral ischemia.

Journal: Neurobiology of disease
Published: January 13, 2025

MRS3997, a dual adenosine A2A/A2B receptor agonist, reduces brain ischemic damage and alleviates neuroinflammation in rats.

MRS3997, a dual adenosine A2A/A2B receptor agonist, reduces brain ischemic damage and alleviates neuroinflammation in rats.

Journal: Neuropharmacology
Published: May 28, 2024

Adenosine A2B receptors differently modulate oligodendrogliogenesis and myelination depending on their cellular localization.

Adenosine A2B receptors differently modulate oligodendrogliogenesis and myelination depending on their cellular localization.

Journal: Glia
Published: November 08, 2023

Pharmacological Characterization of P626, a Novel Dual Adenosine A2A/A2B Receptor Antagonist, on Synaptic Plasticity and during an Ischemic-like Insult in CA1 Rat Hippocampus.

Pharmacological Characterization of P626, a Novel Dual Adenosine A2A/A2B Receptor Antagonist, on Synaptic Plasticity and during an Ischemic-like Insult in CA1 Rat Hippocampus.

Journal: Biomolecules
Published: March 24, 2023
Showing 1-12 of 22

Last Updated: 09/26/2026